[Therapeutic strategy for drug resistant depression].
Inoue
Takeshi
T
Kitaichi
Takeshi
T
Ogawa
Tsutomu
T
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D015306:Biogenic Monoamines / Q000378:metabolism; D016642:Bupropion / Q000627:therapeutic use; D002997:Clomipramine / Q000494:pharmacology / Q000627:therapeutic use; D003866:Depressive Disorder / Q000175:diagnosis / Q000628:therapy*; D018491:Dopamine Agonists / Q000494:pharmacology / Q000627:therapeutic use; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004565:Electroconvulsive Therapy; D006801:Humans; D008094:Lithium / Q000494:pharmacology / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D017729:Presynaptic Terminals / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D012720:Severity of Illness Index; D014284:Triiodothyronine / Q000494:pharmacology / Q000627:therapeutic use
D000928:Antidepressive Agents; D015306:Biogenic Monoamines; D016642:Bupropion; D002997:Clomipramine; D018491:Dopamine Agonists; D008094:Lithium; D008996:Monoamine Oxidase Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors; D014284:Triiodothyronine